EyePoint (EYPT) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

EyePoint

NasdaqGM•Healthcare•Biotechnology

$3.99+0.54(0.16%)Pre-market

Market Cap

$345,306.571

P/S

0.1x

P/B

0.0x

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

How this company scores

WeakMetricSide Score: 28/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (2/25).

Profitability2/25

Growth5/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Interest easily coveredNet cash positionNo share dilution

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 0.1x5y range 0.0x – 21.2x

Currently below its 20-quarter median.

P/B · 0.0x5y range 0.0x – 5.4x

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $345,306.571

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $2.79M
Q. Revenue: $507,000
TTM EBITDA: $-314.38M
TTM Op. Income: $-316.98M
Q. Op. Income: $-97.38M
TTM Net Income: $-306.64M
Q. Net Income: $-94.47M
EPS: $-1.09
Shares Out.: $86,543

$2.79M in TTM revenue declined 94.6% YoY, reaching $507,000 last quarter. TTM EBITDA of $-314.38M and TTM operating income of $-316.98M show growth is flowing through to the bottom line. However, net income is negative at $306.64M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 5 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -19071.0%
Op. Margin: -19207.1%
Net Margin: -18633.1%

Op. margin of -19207.1% is down 18040.3% YoY — costs are rising relative to revenue. Net margin at -18633.1% Across the last 8 quarters, operating margin has fallen for 5 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 0.1x
P/B Ratio: 0.0x

P/S of 0.1x and P/B of 0.0x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $228.19M
Cash: $110.46M
Long-Term Debt: N/A
Book Value: $166.41M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-62.35M
TTM Free Cash Flow: $-271.28M
FCF Margin: -9730.2%
FCF / Net Income: 0.9

TTM FCF of $-271.28M on $-62.35M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is down 40% — an improving trend.